Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. - Test2 - elhamkhani - TriplyDB

Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.

Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.

http://www.wikidata.org/entity/Q33399704

about

Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Novel CD20 monoclonal antibodies for lymphoma therapy A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.Expression levels of TWIST1 are associated with the clinicopathological stage of B-cell non-Hodgkin lymphoma.Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.Antibody therapy of pediatric B-cell lymphoma Target Therapy in Hematological Malignances: New Monoclonal Antibodies.Linked-in: design and efficacy of antibody drug conjugates in oncology Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas.Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.The Central Role for Microenvironment in B-Cell Malignancies: Recent Insights into Synergistic Effects of its Therapeutic Targeting and Anti-CD20 Antibodies.Emerging antibody-drug conjugates for treating lymphoid malignancies.Breakthrough therapies in B-cell non-Hodgkin lymphoma.Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma.Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.DropArray™, a wall-less 96-well plate for uptake and immunofluorescence microscopy, confirms CD22 recycles.Rituximab for the treatment of follicular lymphoma.Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.Novel therapies for aggressive B-cell lymphoma Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned.Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.

P2860

Q24597424-49F89895-6AE4-4C97-8957-90859A84604F Q28390112-C111BD9E-679D-4B45-AC27-4DC0C55D6275 Q33431680-BD132A5A-738F-4D31-AF5A-55C1EE827F96 Q34292362-A345D1A2-8F5D-44A9-BF9A-681E31315653 Q35446333-FC055EE6-A2C8-4641-A881-DAC416A82D57 Q36273796-BE3B678F-6CF2-45DB-8E86-C06DAC17AFFB Q36476080-D394A2C9-280E-457A-B7D6-3FA5D022E0F5 Q36655884-D6AE9D96-CB2C-43D4-BEBA-58D0C0B87CC7 Q36732959-761DB48C-FD61-4DEE-90A3-2A4F3A121A5F Q36979140-E4C48C36-970E-4F65-9610-BBB89D47BEC3 Q37029370-31DD0791-AE0E-4145-80C3-C074E7D098CE Q37296134-203C1E58-A9E1-4C34-BDB5-D709686376A7 Q38068494-EC70BC36-554D-4718-B298-E336BBA5BFCB Q38202691-79933F03-3A64-4E10-94AC-72D2C67865CA Q38204975-54270E7F-B1D7-4B41-B93D-88DB6EFE6400 Q38379829-3AF0E17A-DDDA-40D1-840B-CB315D04CF36 Q38550992-42B7198F-6CB9-4D72-BBE0-1E3FACF57201 Q38577849-64792150-E09D-4F40-AAFD-32F3192CAE74 Q38632313-E47A9914-0DF8-4B9A-8EB9-1CA9F9162C41 Q38708600-44E2118D-27EE-4EFA-A7D8-AC501B3991F5 Q38932868-A49898AF-E846-4A66-86FA-C7C0CF1C5F20 Q38984055-A5B3A035-6779-4BFC-AFB2-4348540B42D5 Q39044402-C3A43EE0-1115-4F58-A957-04495F50F0BE Q39360775-28C8E383-3A24-490F-AF49-DDB79E62CA2A Q41674989-CC43028C-77F8-47FA-87E2-A1F69CDA55AD Q42011578-6539BB49-52D6-41B5-9A94-C832DC0D0E8B Q46209550-35D91741-F98A-44C5-991E-7DD6138958B5 Q48175954-608AFEBE-9797-4878-A020-A04862AE1C7D Q55205941-E93F46F1-6166-49C7-996E-3DC089E7B7E5

P2860

Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.

http://www.wikidata.org/entity/Q33399704

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Phase I study of anti-CD22 imm ...... y B-cell non-Hodgkin lymphoma.

@ast

Phase I study of anti-CD22 imm ...... y B-cell non-Hodgkin lymphoma.

@en

type

label

Phase I study of anti-CD22 imm ...... y B-cell non-Hodgkin lymphoma.

@ast

Phase I study of anti-CD22 imm ...... y B-cell non-Hodgkin lymphoma.

@en

prefLabel

Phase I study of anti-CD22 imm ...... y B-cell non-Hodgkin lymphoma.

@ast

Phase I study of anti-CD22 imm ...... y B-cell non-Hodgkin lymphoma.

@en

P1433

Q33399704-0565F27C-B2D1-4B59-98E7-3CDE30067CEA

P1476

Q33399704-633FA572-7C74-44CB-8221-4B8758DA76D3

P2093

Q33399704-3E310993-4975-4FF7-A17A-D95029C1AF91

Q33399704-47DB6861-D66D-4F4E-A1B5-9C459E574C89

Q33399704-4A9594EC-BAAD-4CC9-8A24-348EF8CD52CC

Q33399704-8465EC23-BCA0-42F6-BAC5-B1D5EC0A674C

Q33399704-B5E81029-B288-42D6-B445-A6AD18ED863B

Q33399704-B98EFD14-2966-4329-883F-852BED08D48A

Q33399704-C1FDE2FD-9E4A-4B26-A27F-F537B23D76A4

Q33399704-F5DEE0E1-FDFA-4349-AA81-2DB5F37F37B1

P2860

Q33399704-156A664A-15EF-456C-B090-6BA589BF64B5

Q33399704-165670CF-6BE8-435C-A89B-9A4A159FB4F7

Q33399704-1AD262F4-7E69-4E9C-BB6A-2D84CEE87F58

Q33399704-56FFED54-6033-48A5-AF9C-CE8D10262AF3

Q33399704-71DEE50A-B3CD-4381-8CBF-776F492CD12F

Q33399704-76628092-15D8-42F0-B79E-EEC0A21E7DDA

Q33399704-83245C47-ACC8-41BF-8782-427CEA182EAA

Q33399704-93C40871-0D35-4CA5-B434-C66361C1E56F

Q33399704-AC5511CF-A14C-40D2-8A13-B9F93258522C

Q33399704-B901E41D-7F09-4A2D-A7E4-2BFDE01AB6F1

P304

Q33399704-B0D51DE4-385F-4793-BBCF-1D57E1379A44

P31

Q33399704-8B6A4745-19DA-4C65-94B0-7A507BF580DE

P356

Q33399704-B6C6EA42-63D3-4C40-AD71-5E04D6134197

P433

Q33399704-DE54327A-8E93-4061-8DC5-9998AA29C766

P478

Q33399704-2B12F8B4-8C6F-4BA6-9493-8024F2B7E871

P577

Q33399704-E0EC7C43-58AD-40BF-ABD6-9A3423A6CD58

P5875

Q33399704-379BD25B-2049-403D-9754-BAAB2BE7D5BA

P698

Q33399704-8A004CD1-97BD-4F4A-82E8-070C56CE72F7

P356

J.1349-7006.2012.02241.X

P1433

P1476

Phase I study of anti-CD22 imm ...... y B-cell non-Hodgkin lymphoma.

@en

P2093

Chiho Ono

http://www.w3.org/2001/XMLSchema#string

Erik Vandendries

http://www.w3.org/2001/XMLSchema#string

Kensei Tobinai

http://www.w3.org/2001/XMLSchema#string

Kiyohiko Hatake

http://www.w3.org/2001/XMLSchema#string

Kiyoshi Ando

http://www.w3.org/2001/XMLSchema#string

Kota Tokushige

http://www.w3.org/2001/XMLSchema#string

Michinori Ogura

http://www.w3.org/2001/XMLSchema#string

Taro Ishibashi

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Antibody pharmacokinetics and pharmacodynamics.

Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.

Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.

Novel agents for follicular lymphoma.

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

P304

933-938

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1349-7006.2012.02241.X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221833392

http://www.w3.org/2001/XMLSchema#string

P698

22335424

http://www.w3.org/2001/XMLSchema#string